BOD Australia (ASX: BOD) has recently completed Phase I clinical trial on its sublingual medicinal cannabis wafer.
The study on 24 healthy volunteers showed the wafer to be safe for human consumption with excellent tolerability characteristics.
Phase I clinical trials assess the the safety of new drugs, not efficacy, and are done on healthy volunteers. This phase also tests multiple doses.
BOD’s wafer was also shown to have faster absorption rates than in oil form, which could show to have benefit to patients who require faster relief.
BOD’s CEO Joe Patterson said, “Results from the Phase I clinical trial of BOD’s cannabis wafer validate the superiority of our product and the tremendous opportunity BOD has as a developer of medicinal cannabis products.
“We have effectively shown that by administering CBD through a sublingual wafer, it is absorbed faster than CBD in oil and compares more favourably to a registered product available in Australia and overseas.
“BOD is now progressing regulatory, commercialisation and export activities with all advancing well. This will underpin a planned scale up in production.”
